Last reviewed · How we verify
MESORIDAZINE BESYLATE
Mesoridazine besylate is an antipsychotic medication that was previously used for the treatment of schizophrenia and other psychotic disorders. It works by blocking dopamine receptors in the brain, which helps to reduce symptoms such as hallucinations and delusions. However, due to its significant side effect profile, including extrapyramidal symptoms and cardiovascular issues, it is no longer widely prescribed. The drug has been withdrawn from the market in many countries, and there is no current FDA-approved label. Despite this, mesoridazine besylate remains a topic of interest in historical and comparative studies of antipsychotic medications.
At a glance
| Generic name | MESORIDAZINE BESYLATE |
|---|---|
| Drug class | Typical antipsychotic |
| Target | 5-hydroxytryptamine receptor 6, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1970 |
Approved indications
- Schizophrenia
Boxed warnings
- Increased risk of extrapyramidal symptoms
- Cardiovascular effects including QT prolongation
Common side effects
Drug interactions
- CYP450 inhibitors (e.g., fluoxetine, paroxetine)
- Other drugs that prolong the QT interval (e.g., certain antiarrhythmics, antidepressants)
Key clinical trials
- Reducing Antipsychotic-Induced Weight Gain in Children With Metformin (PHASE1)
- Antipsychotics and Risk of Hyperglycemic Emergencies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MESORIDAZINE BESYLATE CI brief — competitive landscape report
- MESORIDAZINE BESYLATE updates RSS · CI watch RSS